Skip to main content
Erschienen in: Digestive Diseases and Sciences 6/2012

01.06.2012 | Original Article

Corticosteroid Plus Pentoxifylline Is Not Better than Corticosteroid Alone for Improving Survival in Severe Alcoholic Hepatitis (COPE Trial)

verfasst von: Sandeep Singh Sidhu, Omesh Goyal, Preeti Singla, Dinesh Gupta, Ajit Sood, Rajoo Singh Chhina, Ravinder Kumar Soni

Erschienen in: Digestive Diseases and Sciences | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Corticosteroids and pentoxifylline reduce short-term mortality in severe alcoholic hepatitis (SAH), but not to the extent desired. Combining both drugs may lead to better survival, but has not yet been studied.

Aim

To compare the efficacy of corticosteroids plus pentoxifylline with that of corticosteroids alone in improving survival of SAH patients.

Methods

Of the 111 patients screened, 70 patients with SAH (Maddrey discriminant function (MDF) ≥ 32) were enrolled. Patients with active infection, bleeding, renal failure, or pancreatitis were excluded. Treatment was given for four weeks to group A (n = 36; prednisolone 40 mg/day plus pentoxifylline 400 mg thrice/day) and group B (n = 34; prednisolone 40 mg/day). Patients were followed up for 6 months. Data are expressed as median (range) or percentage.

Results

Baseline characteristics of the two groups were similar (MDF group A 78.5 (36.8–140.9), group B 74.9 (45.6–140.2)). Four-week and six-month survival in groups A and B were not significantly different (four-week 72.2 and 73.5%, respectively, p = 1.00; six-month 30.6 and 23.5%, respectively, p = 0.417). At seven days, 55.6% of patients in group A and 64.7% in group B had a Lille score <0.45 (p = 0.473). Six-month survival was significantly higher for patients with a Lille Score <0.45 than for those with a Lille score ≥0.45 (group A 55.5 vs. 0%, p = 0.0006; group B 36 vs. 0%, p = 0.0304). Biological improvement at 28 days was significant for both groups; however, the difference between the groups was not significant.

Conclusions

For patients with severe alcoholic hepatitis, a combination of corticosteroids and pentoxifylline has no additional survival advantage compared with corticosteroids alone.
Literatur
1.
Zurück zum Zitat Mathurin P. Corticosteroids for alcoholic hepatitis—what’s next? J Hepatol. 2005;43:526–533.PubMedCrossRef Mathurin P. Corticosteroids for alcoholic hepatitis—what’s next? J Hepatol. 2005;43:526–533.PubMedCrossRef
2.
3.
Zurück zum Zitat Taieb J, Mathurin P, Elbim C, et al. Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. J Hepatol. 2000;32:579–586.PubMedCrossRef Taieb J, Mathurin P, Elbim C, et al. Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. J Hepatol. 2000;32:579–586.PubMedCrossRef
4.
Zurück zum Zitat Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med. 1990;172:391–394.PubMedCrossRef Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med. 1990;172:391–394.PubMedCrossRef
5.
Zurück zum Zitat Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis: a meta analysis adjusting for confounding variables. Ann Intern Med. 1990;113:299–307.PubMed Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis: a meta analysis adjusting for confounding variables. Ann Intern Med. 1990;113:299–307.PubMed
6.
Zurück zum Zitat Daures JP, Peray P, Bories P, et al. Corticoid therapy in the treatment of acute alcoholic hepatitis. Results of a meta-analysis. Gastroenterol Clin Biol. 1991;15:223–228.PubMed Daures JP, Peray P, Bories P, et al. Corticoid therapy in the treatment of acute alcoholic hepatitis. Results of a meta-analysis. Gastroenterol Clin Biol. 1991;15:223–228.PubMed
7.
Zurück zum Zitat Mathurin P, Mendenhall CL, Carithers RL Jr, et al. Corticosteroids improve short term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol. 2002;36:480–487.PubMedCrossRef Mathurin P, Mendenhall CL, Carithers RL Jr, et al. Corticosteroids improve short term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol. 2002;36:480–487.PubMedCrossRef
8.
Zurück zum Zitat Mathurin P, O’Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011;60:255–260.PubMedCrossRef Mathurin P, O’Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011;60:255–260.PubMedCrossRef
9.
Zurück zum Zitat Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta analysis adjusting for confounding variables. Gut. 1995;37:113–118.PubMedCrossRef Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta analysis adjusting for confounding variables. Gut. 1995;37:113–118.PubMedCrossRef
10.
Zurück zum Zitat Rambaldi A, Saconato HH, Christensen E, et al. Systematic review: glucocorticosteroids for alcoholic hepatitis—a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther. 2008;27:1167–1178.PubMedCrossRef Rambaldi A, Saconato HH, Christensen E, et al. Systematic review: glucocorticosteroids for alcoholic hepatitis—a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther. 2008;27:1167–1178.PubMedCrossRef
11.
Zurück zum Zitat Imperiale TF, O’Connor J, McCullough AJ. Corticosteroids are effective in patients with severe alcoholic patients. Am J Gastroenterol. 1999;94:3066–3067.PubMedCrossRef Imperiale TF, O’Connor J, McCullough AJ. Corticosteroids are effective in patients with severe alcoholic patients. Am J Gastroenterol. 1999;94:3066–3067.PubMedCrossRef
12.
Zurück zum Zitat Christensen E. Alcoholic hepatitis—glucocorticosteroids or not? J Hepatol. 2002;36:547–548.PubMedCrossRef Christensen E. Alcoholic hepatitis—glucocorticosteroids or not? J Hepatol. 2002;36:547–548.PubMedCrossRef
13.
Zurück zum Zitat Mathurin P. The use of corticosteroids in severe alcohol hepatitis: we need to look beyond this controversy. J Hepatol. 2010;53:392–393.PubMedCrossRef Mathurin P. The use of corticosteroids in severe alcohol hepatitis: we need to look beyond this controversy. J Hepatol. 2010;53:392–393.PubMedCrossRef
14.
Zurück zum Zitat Christensen E. Glucocorticosteroids in acute alcoholic hepatitis: the evidence of a beneficial effect is getting even weaker. J Hepatol. 2010;53:390–391.PubMedCrossRef Christensen E. Glucocorticosteroids in acute alcoholic hepatitis: the evidence of a beneficial effect is getting even weaker. J Hepatol. 2010;53:390–391.PubMedCrossRef
15.
Zurück zum Zitat Mc Cullough AJ, O’ Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol. 1998;93:2022–2036. Mc Cullough AJ, O’ Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol. 1998;93:2022–2036.
16.
Zurück zum Zitat O’Shea RS, McCullough AJ. Treatment of alcoholic hepatitis. Clin Liver Dis. 2005;9:103–134.PubMedCrossRef O’Shea RS, McCullough AJ. Treatment of alcoholic hepatitis. Clin Liver Dis. 2005;9:103–134.PubMedCrossRef
17.
Zurück zum Zitat O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Am J Gastroenterol. 2010;105:14–32.PubMedCrossRef O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Am J Gastroenterol. 2010;105:14–32.PubMedCrossRef
19.
Zurück zum Zitat Doherty GM, Jensen JC, Alexander HR, et al. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery. 1991;110:192–198.PubMed Doherty GM, Jensen JC, Alexander HR, et al. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery. 1991;110:192–198.PubMed
20.
Zurück zum Zitat Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:1637–1648.PubMedCrossRef Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:1637–1648.PubMedCrossRef
21.
Zurück zum Zitat Sidhu SS, Goyal O, Singla M, et al. Pentoxifylline in severe alcoholic hepatitis: a prospective randomized trial. Trop Gastroenterol. 2009;30:S21–S22. Sidhu SS, Goyal O, Singla M, et al. Pentoxifylline in severe alcoholic hepatitis: a prospective randomized trial. Trop Gastroenterol. 2009;30:S21–S22.
22.
Zurück zum Zitat De BK, Gangopadhyay S, Dutta D, et al. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol. 2009;15:1613–1619.PubMedCrossRef De BK, Gangopadhyay S, Dutta D, et al. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol. 2009;15:1613–1619.PubMedCrossRef
23.
Zurück zum Zitat Louvet A, Diaz E, Dharancy S, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol. 2008;48:465–470.PubMedCrossRef Louvet A, Diaz E, Dharancy S, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol. 2008;48:465–470.PubMedCrossRef
24.
Zurück zum Zitat Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23:164–176.PubMedCrossRef Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23:164–176.PubMedCrossRef
25.
Zurück zum Zitat Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365:1790–1800.PubMedCrossRef Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365:1790–1800.PubMedCrossRef
26.
Zurück zum Zitat Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007;45:1348–1354.PubMedCrossRef Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007;45:1348–1354.PubMedCrossRef
27.
Zurück zum Zitat Mathurin P, Abdelnour M, Ramond MJ, et al. Early change in bilirubin levels (ECBL) is an important prognostic factor in severe biopsy proven alcoholic hepatitis (AH) treated by prednisolone. Hepatology. 2003;38:1363–1369.PubMed Mathurin P, Abdelnour M, Ramond MJ, et al. Early change in bilirubin levels (ECBL) is an important prognostic factor in severe biopsy proven alcoholic hepatitis (AH) treated by prednisolone. Hepatology. 2003;38:1363–1369.PubMed
28.
Zurück zum Zitat Mathurin P, Louvet A, Dao T, et al. Addition of pentoxifylline to prednisolone for severe alcoholic hepatitis does not improve 6-month survival: results of the Corpentox trial. Hepatology. 2011;54:81A. Mathurin P, Louvet A, Dao T, et al. Addition of pentoxifylline to prednisolone for severe alcoholic hepatitis does not improve 6-month survival: results of the Corpentox trial. Hepatology. 2011;54:81A.
29.
Zurück zum Zitat Mendenhall C, Roselle GA, Gartside P, et al. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans administration cooperative studies. Alcohol Clin Exp Res. 1995;19:635–641.PubMedCrossRef Mendenhall C, Roselle GA, Gartside P, et al. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans administration cooperative studies. Alcohol Clin Exp Res. 1995;19:635–641.PubMedCrossRef
30.
Zurück zum Zitat Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005;41:353–358.PubMedCrossRef Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005;41:353–358.PubMedCrossRef
31.
Zurück zum Zitat Dureja P, Lucey MR. The place of liver transplantation in the treatment of severe alcoholic hepatitis. J Hepatol. 2010;52:759–764.PubMedCrossRef Dureja P, Lucey MR. The place of liver transplantation in the treatment of severe alcoholic hepatitis. J Hepatol. 2010;52:759–764.PubMedCrossRef
32.
Zurück zum Zitat Singal AK, Bashar H, Anand BS, et al. Graft and patient survival after liver transplantation for alcoholic hepatitis—comparison to alcoholic cirrhosis: exploratory analysis based on UNOS data. Hepatology. 2011;54:162A. Singal AK, Bashar H, Anand BS, et al. Graft and patient survival after liver transplantation for alcoholic hepatitis—comparison to alcoholic cirrhosis: exploratory analysis based on UNOS data. Hepatology. 2011;54:162A.
33.
Zurück zum Zitat Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011;365:1781–1789.PubMedCrossRef Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011;365:1781–1789.PubMedCrossRef
34.
Zurück zum Zitat Brown RS Jr. Transplantation for alcoholic hepatitis—time to rethink the 6-month “rule.” N Engl J Med. 2011;365:1836–1838.PubMedCrossRef Brown RS Jr. Transplantation for alcoholic hepatitis—time to rethink the 6-month “rule.” N Engl J Med. 2011;365:1836–1838.PubMedCrossRef
Metadaten
Titel
Corticosteroid Plus Pentoxifylline Is Not Better than Corticosteroid Alone for Improving Survival in Severe Alcoholic Hepatitis (COPE Trial)
verfasst von
Sandeep Singh Sidhu
Omesh Goyal
Preeti Singla
Dinesh Gupta
Ajit Sood
Rajoo Singh Chhina
Ravinder Kumar Soni
Publikationsdatum
01.06.2012
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 6/2012
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2097-4

Weitere Artikel der Ausgabe 6/2012

Digestive Diseases and Sciences 6/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.